Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real‐World Clinical Study

Immunotherapy is effective and well-tolerated in LE patients with unresectable HCC, particularly in those with preserved liver function (mALBI grade 1/2a). Post-ICI treatment significantly benefits non-LE patients, with limited impact on LE patients, highlighting the need for therapeutic strategies based on age and liver function.

Authors

Institutions

Publication Details

Journal
Cancer Medicine
Published
2025-08-26
DOI
https://doi.org/10.1002/cam4.71171
Citations
1
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
1.32

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real‐World Clinical Study

Taro Watabe, Kento Inada, Mao Tsuchiya, Takashi Fujii et al.
1 citations
Cancer Medicine
Hepatocellular Carcinoma Treatment and Prognosis
1.32
article

Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real‐World Clinical Study

Taro Watabe, Kento Inada, Mao Tsuchiya, Takashi Fujii, Keiichi Akahoshi, Daisuke Ban, Taro Shimizu, Shun Kaneko, Akiko Kusano‐Kitazume, Hideki Watanabe, Miyako Murakawa, Mina Nakagawa, Junko Fujiki, Sei Kakinuma, Kozue Uchidate, Tsubasa Nobusawa, Takehito Asakawa, Shinya Oooka, Isamu Shibata, Fukiko Kawai‐Kitahata, Tomohiro Mochida, Ryuichi Okamoto, Jun Tsuchiya, Keiya Watakabe, Yasuhiro Asahina, Shunsuke Ueyama, Chiaki Maeyashiki, Sayuri Nitta, Sho Watanabe, Ayako Sato, Hitoshi Kurata, Masato Miyoshi
article en
1 citations

Abstract

Immunotherapy is effective and well-tolerated in LE patients with unresectable HCC, particularly in those with preserved liver function (mALBI grade 1/2a). Post-ICI treatment significantly benefits non-LE patients, with limited impact on LE patients, highlighting the need for therapeutic strategies based on age and liver function.

Cancer MedicineVol. 14(17)
Tokyo Institute of Technology (JP), Toho University (JP), Tokyo Metropolitan Ohtsuka Hospital (JP), Tokyo Institute of Psychiatry (JP), Tsuchiura Kyodo General Hospital (JP), Toho University Omori Medical Center (JP), Showa General Hospital (JP), Tokyo Metropolitan Bokutoh Hospital (JP), Tokyo Metropolitan Hiroo Hospital (JP), JA Toride Medical Center (JP), Kure Kyosai Hospital (JP), National Hospital Organization (JP), Yokohama Municipal Minato Red Cross Hospital (JP), Yokosuka Kyosai Hospital (JP), Musashino Red Cross Hospital (JP), Tokyo Metropolitan Tama Medical Center (JP), National Disaster Medical Center (JP), Soka Municipal Hospital (JP), Tokyo Rosai Hospital (JP), Kashiwa Municipal Hospital (JP), Institute of Science Tokyo (JP)
Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science
Openalex Percentile: Top 17%
Hepatocellular Carcinoma Treatment and Prognosis
1.32
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.